It has been a privilege for the company to participate in the 12th National Bank of Greece Seeds competition and a great honor to receive the first award for our metastasis detection system that provides decision support on the staging of breastcancer, coloncancer, lungcancer as well as melanoma patients. The system is called DeepPath™-LYDIA, received cemarking [...]
We are super excited to announce that DeepMedIO receives CE marking for DeepPath™ - LYDIA. The system got regulatory clearance as decision support as per IVDD for helping histopathologists detect metastases on Hematoxylin & Eosin stained lymph nodes from patients with breast cancer, colon cancer, lung cancer, and melanoma. We must note that to the best [...]
We are happy to announce that DeepMed IO as part of a consortium consisting of MIDA Biotech B.V. (an Orgenesis Inc. company), Leiden University, and MIRCOD LLC, acquired a €4m Pathfinder grant from European Innovation Council and SMEs Executive Agency (EISMEA) for the development of an Ai-powered platform to democratize autologous IPCS manufacturing! This is a [...]
DeepMed IO was part of the Hellenic Ministry of Development and Investments delegation in the United Arab Emirates led by the Deputy Minister Dr. Christos Dimas. We presented our company at the Expo 2020 Dubai, and had multiple meetings with individuals from the academic community as well as from major accelerators and Investement funds like Dubai [...]
DeepMed IO through its Greek-Branch participated in Thessaloniki International Fair supported by Elevate Greece and ΓΓΕΚ. We were given the chance to present DeepPath(TM)-LYDIA, our close-to-market ΑΙ-powered decision support system for βreastcancer staging, and got to interact with the greek startup medtech ecosystem. What a great experience!